Hemostemix Stock Probability of Future Stock Price Finishing Over 33.43
| HEM Stock | CAD 0.07 0.01 12.50% |
Hemostemix |
Hemostemix Target Price Odds to finish over 33.43
The tendency of Hemostemix Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over C$ 33.43 or more in 90 days |
| 0.07 | 90 days | 33.43 | close to zero percent |
Based on a normal probability distribution, the odds of Hemostemix to move over C$ 33.43 or more in 90 days from now is close to zero percent (This Hemostemix probability density function shows the probability of Hemostemix Stock to fall within a particular range of prices over 90 days) . Probability of Hemostemix price to stay between its current price of C$ 0.07 and C$ 33.43 at the end of the 90-day period is about 83.32 .
Assuming the 90 days horizon Hemostemix has a beta of -0.31. This usually indicates as returns on the benchmark increase, returns on holding Hemostemix are expected to decrease at a much lower rate. During a bear market, however, Hemostemix is likely to outperform the market. Additionally Hemostemix has an alpha of 0.0953, implying that it can generate a 0.0953 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Hemostemix Price Density |
| Price |
Predictive Modules for Hemostemix
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Hemostemix. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Hemostemix Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Hemostemix is not an exception. The market had few large corrections towards the Hemostemix's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Hemostemix, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Hemostemix within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.1 | |
β | Beta against Dow Jones | -0.31 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | 0.01 |
Hemostemix Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Hemostemix for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Hemostemix can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Hemostemix had very high historical volatility over the last 90 days | |
| Hemostemix has some characteristics of a very speculative penny stock | |
| Hemostemix has high likelihood to experience some financial distress in the next 2 years | |
| Hemostemix has accumulated 4.32 M in total debt. Hemostemix has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Hemostemix until it has trouble settling it off, either with new capital or with free cash flow. So, Hemostemix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hemostemix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hemostemix to invest in growth at high rates of return. When we think about Hemostemix's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hemostemix has accumulated about 49.36 K in cash with (1.5 M) of positive cash flow from operations. | |
| Latest headline from news.google.com: Hemostemix Reveals Breakthrough 47 percent Heart Function Boost with Revolutionary Blood-Based Treatment - StockTitan |
Hemostemix Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Hemostemix Stock often depends not only on the future outlook of the current and potential Hemostemix's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Hemostemix's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 82.5 M | |
| Cash And Short Term Investments | 155.4 K |
Hemostemix Technical Analysis
Hemostemix's future price can be derived by breaking down and analyzing its technical indicators over time. Hemostemix Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Hemostemix. In general, you should focus on analyzing Hemostemix Stock price patterns and their correlations with different microeconomic environments and drivers.
Hemostemix Predictive Forecast Models
Hemostemix's time-series forecasting models is one of many Hemostemix's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Hemostemix's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Hemostemix
Checking the ongoing alerts about Hemostemix for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Hemostemix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Hemostemix had very high historical volatility over the last 90 days | |
| Hemostemix has some characteristics of a very speculative penny stock | |
| Hemostemix has high likelihood to experience some financial distress in the next 2 years | |
| Hemostemix has accumulated 4.32 M in total debt. Hemostemix has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Hemostemix until it has trouble settling it off, either with new capital or with free cash flow. So, Hemostemix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hemostemix sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hemostemix to invest in growth at high rates of return. When we think about Hemostemix's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hemostemix has accumulated about 49.36 K in cash with (1.5 M) of positive cash flow from operations. | |
| Latest headline from news.google.com: Hemostemix Reveals Breakthrough 47 percent Heart Function Boost with Revolutionary Blood-Based Treatment - StockTitan |
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.